74 results about "Fulvestrant" patented technology

This invention relates to the treatment of androgen receptor-positive breast cancer in a subject, for example a female subject. Accordingly, this invention provides methods of: a) treating a subject suffering from breast cancer; b) treating a subject suffering from metastatic breast cancer; c) treating a subject suffering from refractory breast cancer; d) treating a subject suffering from AR-positive breast cancer; e) treating a subject suffering from AR-positive refractory breast cancer; f) treating a subject suffering from AR-positive metastatic breast cancer; g) treating a subject suffering from AR-positive and ER-positive breast cancer; h) treating a subject suffering from triple negative breast cancer; i) treating a subject suffering from advanced breast cancer; j) treating a subject suffering from breast cancer that has failed SERM (tamoxifen, toremifene), aromatase inhibitor, trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, exemestane (Aromasin), bevacizumab (Avastin), and / or fulvestrant treatments; k) treating, preventing, suppressing or inhibiting metastasis in a subject suffering from breast cancer; l) prolonging survival of a subject with breast cancer, and / or m) prolonging the progression-free survival of a subject with breast cancer; comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound, comprising administering to the subject a therapeutically effective amount of a SARM compound of this invention.

The invention relates to a pharmaceutical composition of fulvestrant. The pharmaceutical composition comprises: (1) fulvestrant; (2) at least one pharmaceutically acceptable alcohol; (3) medium-chain triglyceride; and (4) a castor oil matrix.

The invention relates to a fulvestrant pharmaceutical composition. Specifically, the invention relates to the fulvestrant-containing pharmaceutical composition for intramuscular injection, wherein the pharmaceutical composition comprises 1) fulvestrant, 2) a castor oil matrix; 3) at least one pharmaceutically acceptable alcohol, and 4) one or any mixture selected from the group consisting of medium-chain triglyceride, triglycerol caprylate-caprate, glyceryl triacetate, ethyl acetate and isopropyl myristate. The pharmaceutical composition is excellent in pharmaceutical safety and stability performance, and better in bioavailability.

The invention discloses a new fulvestrant synthesis method, which comprises the following steps: by taking an intermediate X and pentafluoropentanol as starting materials, carrying out four-step reaction to obtain fulvestrant; the column chromatography purification is not required in the route, the fulvestrant meeting the pharmacopoeia criterion can be obtained only by recrystallizing the crude final product, the total yield achieves 50-60%, raw materials are all industrial products and easily available, and the quality is easily controlled.

The present invention relates to novel fulvestrant formulations comprising one or more of a propylene glycol or a pharmaceutically acceptable polyethylene glycol.

The invention relates to a fulvestrant containing oil needle preparation for intramuscular injection. An excipient of the oil needle preparation is corn oil for injection. The oil needle preparation is filled in a glass ampoule bottle under an aseptic condition. The fulvestrant containing oil needle preparation has the advantages that as the excipient, the corn oil for injection is considered as a totally non-toxic and non-irritating substance; and relevant side effects caused by long-term contacts of the excipient, pharmaceutically acceptable alcohols and non-aqueous ester solvents with plastic products are avoided by selecting the glass ampoule bottle to contain the oil needle preparation.

Fulvestrant nanosphere / microsphere and preparation method and use thereof are provided in the present invention. The carrier material of the fulvestrant nanosphere / microsphere is methoxy ended polyethylene glycol-polylactic acid block copolymer. The nanosphere / microsphere is prepared by solvent-nonsolvent method, in-liquid drying method and / or spray drying method, and has the features of high drug loading and high encapsulation efficiency, controllable release of medicine and no irritant to application site or blood vessel. The fulvestrant nanosphere / microsphere can be used to treat metastatic advanced breast cancer in post-menopausal woman.

The invention relates to a solid pharmaceutical composition comprising solid amorphous fulvestrant, said composition being formulated in combination with a solubilizing composition. The invention also relates to a method for preparing said composition and a kit including the composition.

This invention relates to the treatment of breast cancer in a subject, for example a female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed SERM (tamoxifen, toremifene), aromatase inhibitor, palbociclib (Ibrance), trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, exemestane (Aromasin), bevacizumab (Avastin), and / or fulvestrant treatments; metastasis in a subject suffering from breast cancer; and / or HER2-positive; comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound.

The invention relates to a pharmaceutical composition of fulvestrant. The pharmaceutical composition comprises: (1) fulvestrant; (2) at least one pharmaceutically acceptable alcohol; (3) medium-chain triglyceride; and (4) a castor oil matrix.

This invention relates to the treatment of breast cancer in a subject, for example a female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed SERM (tamoxifen, toremifene), aromatase inhibitor, trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, exemestane (Aromasin), bevacizumab (Avastin), and / or fulvestrant treatments; metastasis in a subject suffering from breast cancer; comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound.

This invention relates to the treatment of androgen receptor-positive breast cancer in a subject, for example a female subject. Accordingly, this invention provides methods of: a) treating a subject suffering from breast cancer; b) treating a subject suffering from metastatic breast cancer; c) treating a subject suffering from refractory breast cancer; d) treating a subject suffering from AR-positive breast cancer; e) treating a subject suffering from AR-positive refractory breast cancer; f) treating a subject suffering from AR-positive metastatic breast cancer; g) treating a subject suffering from AR-positive and ER-positive breast cancer; h) treating a subject suffering from triple negative breast cancer; i) treating a subject suffering from advanced breast cancer; j) treating a subject suffering from breast cancer that has failed SERM (tamoxifen, toremifene), aromatase inhibitor, trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, exemestane (Aromasin), bevacizumab (Avastin), and / or fulvestrant treatments; k) treating, preventing, suppressing or inhibiting metastasis in a subject suffering from breast cancer; l) prolonging survival of a subject with breast cancer, and / or m) prolonging the progression-free survival of a subject with breast cancer; comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound, comprising administering to the subject a therapeutically effective amount of a SARM compound of this invention.

This invention relates to the treatment of breast cancer in a subject, for example a female subject. The breast cancer includes metastatic breast cancer, refractory breast cancer, AR-positive breast cancer, AR-positive refractory breast cancer, AR-positive metastatic breast cancer, AR-positive and ER-positive breast cancer, triple negative breast cancer, advanced breast cancer, breast cancer that has failed SERM (tamoxifen, toremifene), aromatase inhibitor, trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, exemestane (Aromasin), bevacizumab (Avastin), and / or fulvestrant treatments, and metastasis in a subject suffering from breast cancer. The method comprises administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound.

Combinations of betaine and vitamin C are used to suppress or prevent malignant tumors or to treat viruses, e.g., by combining the two ingredients in a product consumed by a human, dog, or cat, such as an aqueous liquid such as grape juice, the ingredients being provided in containers with instructions for use, or in finished products, especially with support of tests demonstrating the effectiveness of the treatment for, e.g., preventing tumors in populations known to be at risk of developing tumors, or, treating existing cancers in combination with other cancer drugs such as anastrozole and / or fulvestrant and / or artemisinin either concurrently or sequentially to prevent the cancer from growing when the cancer drug is not being used, or in the treatment of viruses.

The invention discloses a faslodex controlled-release microballoon preparation method. The faslodex controlled-releasemicroballoon in the invention envelopes fulvestrant takes PLA or PLGA or PCL or other biodegradable materials as the carrier materials. Besides, the invention takes PVA or the miscible liquids of PCL and Tween 80 as the disperse medium. Then, with the emulsion solvent evaporation method, finish the preparation of fulvestrant controlled-release microballoon under the action of mechanical mixing or high-speed shearing. The microballoon has spherical shape and even distribution of grain size that is controllable within the scope of 15 to 125Mu m as well as reaches a drug-loading rate of over 7 per cent and encapsulation rate of over 80 per cent.

The present invention relates to a process for the preparation of Fulvestrant which includes recovering the by-products deriving from the oxidation of the corresponding sulfide and then subjecting the by-products to a reduction reaction in the presence of specific reducing agents.

This invention relates to the treatment of breast cancer in a subject, for example a female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed SERM (tamoxifen, toremifene), aromatase inhibitor, palbociclib (Ibrance), trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, exemestane (Aromasin), bevacizumab (Avastin), and / or fulvestrant treatments; metastasis in a subject suffering from breast cancer; and / or HER2-positive; comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound.

The inventive subject matter provides ready to inject fulvestrant compositions with improved solubility and stability, and methods for preparing the same. Contemplated compositions include fulvestrantat a concentration of greater than 100 mg / ml, and maintain degradation of the fulvestrant at a level of less than 5 wt% when stored over at least three months at 25 DEG C.